Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2021

STOCK-BASED COMPENSATION

Schedule of Accounting for Stock-Based Compensation


		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2021			2020			2021			2020

Employee and director stock option grants:
Research and development		$	41,400		$	3,478		$	70,795		$	27,213
General and administrative			159,217			89,165			254,386			209,576
Total stock-based compensation		$	200,617		$	92,643		$	325,181		$	236,789

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


							Weighted
		Number of					Average
		Shares Issuable					Remaining
		Upon Exercise		Weighted			Contracted		Aggregate
		of Outstanding		Average			Term in		Intrinsic
		Options		Exercise Price			Years		Value
Outstanding at December 31, 2020		1,184,464		$	4.34				$	316,688
Granted		208,500		$	1.78
Outstanding at March 31, 2021		1,392,964		$	3.96		8.56		$	122.700
Granted		3,309,000		$	1.66
Expired		(177)		$	2,800.00
Outstanding at June 30, 2021		4,701,787		$	2.23		9.31		$	—

Exercisable, June 30, 2021		701,870		$	5.34		7.67		$	—
Unvested, June 30, 2021		3,999,917		$	1.69		9.59		$	—

Schedule of Restricted Stock Grants


				Weighted
				Average
				Grant Date			Total Grant
		Number of		Fair Value			Date Fair
		Shares		Per Share			Value
Outstanding at December 31, 2019		9,334		$	21.00		$	196,000
Vested		(9,334)		$	21.00		$	(196,000)
Outstanding at December 31, 2020		—		$	—		$	—